Privia PRVA NASDAQ · Healthcare · United States
$24.55 +3.72% +$0.88
Summary
53 / 100 · Bulios Score
What speaks for it
- Revenue grew by 16% a year over the last 3 years.
- It holds more cash than debt: $446.3M against $8.26M.
- Analysts expect revenue to grow by 19% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- Out of every 100 USD of revenue, only 1.4 USD is left as net profit.
- It missed profit estimates 5 times in the last 8 quarters.
- It earns only 3.6 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 87.0 USD for 1 USD of yearly profit. Over the last five years it was 142.8 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 21% a year over 5 years. Over the last 3 years it grew by 16% a year. For the next fiscal year analysts expect revenue to grow by 19%.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 89 USD
- Sales and administration 8.4 USD
- Taxes and other 0.7 USD
- Net profit 1.4 USD
Net profit, industry median (Medical - Healthcare Information Services) 5.7 USD
Out of every 100 USD of revenue, 1.4 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 20
- Hold 2
- Sell 0
Today's price within the analysts' price targets
The average target of $28 is 14% above today's price. 91% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- FFS-Patient Care 64%
- Capitated Revenue 15%
- Shared Savings 11%
- FFS-Administrative Services 6.5%
- Care Management Fee (PMPM) 3.4%
- Other 0.4%
By region
The company reports no revenue by region.
FFS-Patient Care brings in 64% of revenue. Shared Savings grew fastest, by 30% a year.
Segments in detail